Hostname: page-component-89b8bd64d-b5k59 Total loading time: 0 Render date: 2026-05-09T09:23:57.721Z Has data issue: false hasContentIssue false

Vitamins and Infusion of Levodopa-Carbidopa Intestinal Gel

Published online by Cambridge University Press:  20 April 2021

Jennifer Taher
Affiliation:
Department of Pathology & Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
Taline Naranian
Affiliation:
Edmond J. Safra Program in Parkinson’s Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada
Yu-Yan Poon
Affiliation:
Edmond J. Safra Program in Parkinson’s Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada
Aristide Merola
Affiliation:
Department of Neurology, Ohio State University, Columbus, Ohio, USA
Tiago Mestre
Affiliation:
Division of Neurology, Department of Medicine, University of Ottawa, The Ottawa Hospital Ottawa, Ottawa, Ontario, Canada University of Ottawa Brain and Mind Research Institute, Ottawa, Ontario, Canada The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Oksana Suchowersky
Affiliation:
Department of Medicine (Neurology), Medical Genetics and Pediatrics, University of Alberta, Edmonton, Alberta, Canada
Vathany Kulasingam
Affiliation:
Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada Laboratory Medicine Program, University Health Network, Toronto, Ontario, Canada
Alfonso Fasano*
Affiliation:
Edmond J. Safra Program in Parkinson’s Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada Division of Neurology, University of Toronto, Toronto, Ontario, Canada Krembil Brain Institute, Toronto, Ontario, Canada
*
Correspondence to: Dr. Alfonso Fasano, MD, PhD., Chair in Neuromodulation and Multi-Disciplinary Care, Professor – University of Toronto, Clinician Investigator – Krembil Research Institute, Movement Disorders Centre – Toronto Western Hospital, 399 Bathurst St, 7McL412, Toronto, ON, M5T 2S8, Canada. Email: alfonso.fasano@uhn.ca
Rights & Permissions [Opens in a new window]

Abstract:

Levodopa-carbidopa intestinal gel infusion (LCIG) is an established therapy for advanced Parkinson disease (PD), resulting in a significant improvement of quality of life. With increased LCIG adoption worldwide, potential complications due to abnormal vitamin absorption or metabolism have been reported in these patients. Neurologists are unfamiliar with vitamins physiology and pathophysiological mechanisms in case of their deficiency. Unfortunately, clinical and laboratory guidelines related to vitamin monitoring and supplementation in the context of treatment with LCIG are not available. We herein summarize the current knowledge on three vitamins that are reduced with LCIG therapy reporting on their physiology, laboratory testing, and clinical impact of their deficiency/excess. In addition, we proposed an opinion-based recommendation for clinicians treating LCIG patients. Patients and caregivers should be informed about the risk of vitamin deficiency. Vitamin B12, homocysteine, and methylmalonic acid (MMA) should be tested before starting LCIG, six months after and once/year thereafter. Vitamin B6 and folate testing is not universally available but it should be considered if homocysteine is elevated but MMA and/or total vitamin B12 are normal. Prophylaxis of vitamin deficiency should be started as soon as LCIG is implemented, possibly even before. Dietary recommendations are enough in most patients although a subgroup of patients is at higher risk and should receive Vitamin B12 regularly and cycles of B6. Finally, once diagnosed a vitamin deficiency should be readily treated and accompanied by clinical and laboratory monitoring. Resistant cases should receive non-oral routes of administration and possibly discontinue LCIG, even temporarily.

Résumé :

RÉSUMÉ :

Les vitamines et l’administration intestinale de lévodopa-carbidopa en gel.

L’administration de gel intestinal de lévodopa-carbidopa (GILC) est un traitement avéré de la maladie de Parkinson rendue à un stade avancé, qui permet une amélioration sensible de la qualité de vie. Compte tenu de l’adoption accrue du traitement par le GILC dans le monde, la documentation médicale fait état d’un certain nombre de complications possibles du traitement en raison d’un dysfonctionnement de l’absorption des vitamines ou du métabolisme. Or les neurologues connaissent peu la physiologie de l’absorption des vitamines et la physiopathologie des carences. Malheureusement, il n’existe pas de lignes directrices sur la conduite clinique ou les analyses de laboratoire relatives à la surveillance de l’absorption des vitamines et à la supplémentation dans le contexte du traitement par le GILC. Aussi présenterons-nous dans l’article un résumé des connaissances actuelles sur la malabsorption de trois vitamines liée au traitement par le GILC, en ce qui concerne la physiologie, les analyses de laboratoire et la portée clinique d’une carence ou d’un excès vitaminiques. Suivra une recommandation fondée sur des avis à l’intention des cliniciens qui ont à traiter des patients par le GILC. Ces derniers et leurs aidants devraient être informés du risque de carence en vitamine. Ainsi, il faudrait prescrire un dosage de la vitamine B12, de l’homocystéine et de l’acide méthylmalonique (AMM) avant même le début du traitement, puis six mois plus tard et enfin une fois par année par la suite. Le dosage de la vitamine B6 et du folate n’est pas offert partout, mais il faudrait l’envisager si le taux d’homocystéine est élevé mais que celui d’AMM et/ou la teneur totale en vitamine B12 restent dans la normale. En outre, des mesures prophylactiques d’une carence en vitamines devraient être mises en œuvre dès l’instauration du traitement par le GILC, et idéalement même avant. Quant aux recommandations sur l’alimentation, elles suffisent en général, mais il existe un sous-groupe de malades prédisposé à la malabsorption, qui devrait recevoir régulièrement de la vitamine B12 et être soumis à des cycles d’administration de la vitamine B6. Enfin, dès qu’un diagnostic de carence en vitamine est posé, il faudrait entreprendre le traitement sans tarder, complété par un suivi clinique et des analyses de laboratoire. Dans les cas rebelles, il faudrait choisir des voies d’administration non orales, voire l’arrêt, même temporaire, du traitement par le GILC.

Information

Type
Review Article
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation
Figure 0

Figure 1: Survey among healthcare professionals treating LCIG patients. On February 1, 2020, 56 nurses, neurologists, gastroenterologists and neurology fellows from across Canada with an interest in PD and LCIG gathered in Toronto to exchange best practices. Before (by email) and during (by electronic poll) the meeting, an anonymous survey was conducted in order to capture the attitude of the attendees with respect to vitamins monitoring and supplementation. Abbreviations: *: e.g. patients at risk, patients with pre-existing neuropathy, etc., **: multivitamins provided, #: multiple choices allowed, ##: 97% of the interviewees do not order NCS in non-symptomatic patients (e.g., without neuropathy), CBC: complete blood count, INR: international normalized ratio, LCIG: levodopa-carbidopa intestinal gel, MMA: methylmalonyl CoA, NCS: nerve conduction studies, Pts: patients.

Figure 1

Figure 2: Homocysteine metabolism. 5-MTHF, 5-methyltetrahydrofolate; 5,10-MTHF, 5,10-methylene tetrahydrofolate; BHMT; betaine homocysteine methyltransferase; CBS, cystathionine beta-synthase; CT, cystathionine; MS, methionine synthase, MTHFR, methyl tetrahydrofolate reductase; SHMT, serine hydroxymethyltransferase.

Figure 2

Figure 3. Metabolic reactions involving cobalamin coenzymes. A. Conversion of homocysteine to methionine linking vitamin B12 (methylcobalamin) and folate metabolic pathways. B. Conversion of MMA to succinylCoa. THF; tetrahydrofolate.

Figure 3

Table 1. Function, dietary source, symptoms of deficiency and lab testing for vitamin B6, B7 and B12

Figure 4

Figure 4. Levodopa depletion of methyl reserves from the homocysteine metabolic pathway. DDC, dopamine decarboxylase; MS, methionine synthase. Adapted from Refs.5,59

Figure 5

Table 2: Recommendations for monitoring, prophylaxis, and treatment of vitamin-related LCIG complications

Figure 6

Table 3: Synopsis of laboratory results in vitamin B6, B9 (folate), and B12 deficiency*